RxDoctor Payments Data

Gary Weiner, MD

Ophthalmology · Salina, KSNPI 1336143213

Payments from drug & device makers

What this record shows

13 manufacturers reported payments, led by Carl Zeiss Meditec USA, Inc. at 40.8% of the total. Reporting peaked in 2024 at $2,703 and has fallen 70.0% since, to $811 in 2025.

$4,398in general payments, 2019–2025

Across 81 payments — averaging $54.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Carl Zeiss Meditec USA, Inc.$2K
  • Alcon$1K
  • AbbVie$842
  • Amgen$117
  • Dompe US, Inc.$116
  • Bausch & Lomb Americas Inc.$83
  • plus $312 from 7 others

What the payments were for

  • Travel & lodging$2,20750%
  • Food & beverage$2,19150%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,398 in reported general payments places this provider in the 80th percentile of 135 ophthalmology providers in Kansas.

See all ophthalmology providers in Kansas

Medicare billing

Part B allowed, 2024
$561,632
Medicare patients
1,120
Services billed
6,012

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost48$16,565
RocklatanNetarsudil Mesylat/Latanoprost35$15,386
CombiganBrimonidine Tartrate/Timolol24$7,355
VyzultaLatanoprostene Bunod22$6,670
Alphagan PBrimonidine Tartrate14$6,174
RhopressaNetarsudil Mesylate12$5,438
Travoprost40$4,690
Loteprednol Etabonate16$3,162
Latanoprost462$2,621
SimbrinzaBrinzolamide/Brimonidine Tart12$2,472
Difluprednate20$2,234
Timolol Maleate353$2,056
Prednisolone Acetate63$1,851
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat83$1,426
Brimonidine Tartrate85$1,365

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Combigan, Alphagan P$842$30,09486 claims
Bausch & Lomb Americas Inc.Vyzulta$83$6,67022 claims
AlconSimbrinza$1,135$2,47212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 135 ophthalmology providers in Kansas.

Other ophthalmology in Salina

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →